SG11201902988UA - Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof - Google Patents

Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Info

Publication number
SG11201902988UA
SG11201902988UA SG11201902988UA SG11201902988UA SG11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA
Authority
SG
Singapore
Prior art keywords
compositions
international
methods
novel
pct
Prior art date
Application number
SG11201902988UA
Inventor
Frank Bedu-Addo
Greg Conn
Martin Ward
Jerold Woodward
Original Assignee
Pds Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pds Biotechnology Corp filed Critical Pds Biotechnology Corp
Publication of SG11201902988UA publication Critical patent/SG11201902988UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

International Patent Classification: A61K 38/00 (2006.01) C07K 14/00 (2006.01) A61K 39/12 (2006.01) A61K 9/127 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/US2017/055119 1218k9 OStim # # I _r_71111M 11 s-7 ,• (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo omoiloo Em Eno iflo oimIE (10) International Publication Number WO 2018/067689 Al 04 October 2017 (04.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/404,458 05 October 2016 (05.10.2016) US (71) Applicant: PDS BIOTECHNOLOGY CORPO- RATION [US/US]; 675 US Highway 1, North Brunswick, NJ 08902 (US). (72) Inventors: BEDU-ADDO, Frank; 24 Tamar Lane, Stam- ford, CT 06905 (US). CONN, Greg; Orense 17, Esc. Dcha. 4 Dcha., 28020 Madrid (ES). WARD, Martin; 4513 Dothan Drive, Lexington, KY 40515 (US). WOOD- WARD, Jerold; 611 Ballard Street, Lexington, KY 40508 (US). (74) Agent: KULKARNI, Sima, Singadia; DLA Piper LLP (US), 1650 Market Street, Suite 4900, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: NOVEL HPV16 NON HLA-RESTRICTED T-CELL VACCINES, COMPOSITIONS AND METHODS OF USE THERE- OF FIGURE 1 2 3 5 7 9 2 3 5 79 2 3 5 7 9 2 3 5 7'9 2 5 7 2 3 5 7 9 C Subject 2-1 2-2 2-3 5-1 5-2 5-1 00 N O (57) : Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and 0 cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immuno- \" genic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as C cationic lipids. [Continued on next page] fT X Ci) 800.00 700.00 600.00 500.00 400.00 300.00 200.00 100.00 1-1 13.00 Visit WO 2018/067689 Al MIDE111111111101111111111111111111111111111111 11111 11111 H11111110 111110111111111111 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201902988UA 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof SG11201902988UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404458P 2016-10-05 2016-10-05
PCT/US2017/055119 WO2018067689A1 (en) 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201902988UA true SG11201902988UA (en) 2019-05-30

Family

ID=61757761

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201902988UA SG11201902988UA (en) 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Country Status (12)

Country Link
US (2) US11401306B2 (en)
EP (1) EP3522908A4 (en)
JP (3) JP7165652B2 (en)
KR (1) KR20190073416A (en)
CN (1) CN110035765B (en)
AU (2) AU2017340407A1 (en)
BR (1) BR112019006831A2 (en)
CA (1) CA3039211A1 (en)
IL (1) IL265833A (en)
MX (1) MX2019003961A (en)
SG (1) SG11201902988UA (en)
WO (1) WO2018067689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
ES2712505T3 (en) 2008-04-17 2019-05-13 Pds Biotechnology Corp Stimulation of an immune response by enantiomers of cationic lipids
JP2015530413A (en) 2012-09-21 2015-10-15 ベデュ−アッド，フランク Improved vaccine compositions and methods of use
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2021505606A (en) * 2017-12-05 2021-02-18 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ A method for stimulating the type I interferon gene and a composition containing a cationic lipid.
AU2020204779A1 (en) * 2019-01-03 2021-08-26 Evaxion Biotech A/S Vaccines targeting neoepitopes
CN112110995A (en) * 2019-06-19 2020-12-22 上海交通大学医学院 Tumor neoantigen polypeptide and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) * 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
DE60238864D1 (en) * 2001-11-07 2011-02-17 Mankind Corp FOR EPITOPES OF ANTIGENIC ENCODING EXPRESSION VECTORS AND METHOD FOR THEIR DESIGN
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
WO2007121895A2 (en) 2006-04-21 2007-11-01 Transgene S.A. Hpv-16-based papillomavirus vaccine
EP2757109B1 (en) * 2007-05-31 2019-07-10 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
WO2010132867A1 (en) * 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
TWI673062B (en) * 2011-09-12 2019-10-01 美商Ｐｄｓ生技公司 Particulate vaccine formulations
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
JP6348489B2 (en) 2012-06-15 2018-07-04 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Cationic lipid vaccine composition and methods of use
JP2015530413A (en) * 2012-09-21 2015-10-15 ベデュ−アッド，フランク Improved vaccine compositions and methods of use
JP6788500B2 (en) * 2013-10-23 2020-11-25 アメリカ合衆国 HLA-A24 Agonist Epitope and Composition of MUC1-C Cancer Protein and Method of Use
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Also Published As

Publication number Publication date
CN110035765B (en) 2024-04-02
JP7165652B2 (en) 2022-11-04
US20220332768A1 (en) 2022-10-20
JP2022191472A (en) 2022-12-27
EP3522908A1 (en) 2019-08-14
IL265833A (en) 2019-06-30
US11401306B2 (en) 2022-08-02
AU2017340407A1 (en) 2019-05-02
AU2021200200A1 (en) 2021-03-18
EP3522908A4 (en) 2020-06-24
MX2019003961A (en) 2019-08-26
JP7397945B2 (en) 2023-12-13
US20180094032A1 (en) 2018-04-05
CN110035765A (en) 2019-07-19
JP2019533658A (en) 2019-11-21
WO2018067689A1 (en) 2018-04-12
JP2024023507A (en) 2024-02-21
BR112019006831A2 (en) 2019-07-30
KR20190073416A (en) 2019-06-26
CA3039211A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201803906PA (en) Control of cellular redox levels
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811432WA (en) Rna for cancer therapy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201901126UA (en) Combination therapy for cancer
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201909311TA (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof